levofloxacin has been researched along with disulfiram in 7 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (disulfiram) | Trials (disulfiram) | Recent Studies (post-2010) (disulfiram) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 3,776 | 175 | 723 |
| Protein | Taxonomy | levofloxacin (IC50) | disulfiram (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 10.1 | |
| Spike glycoprotein | Betacoronavirus England 1 | 9.35 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 9.35 | |
| type-1 angiotensin II receptor | Homo sapiens (human) | 6.637 | |
| perilipin-5 | Homo sapiens (human) | 1.622 | |
| perilipin-1 | Homo sapiens (human) | 6.959 | |
| apelin receptor | Homo sapiens (human) | 2.63 | |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | 4.2905 | |
| bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase | Mycobacterium tuberculosis H37Rv | 85.03 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 9.35 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Carbamate kinase | Giardia intestinalis | 0.6 | |
| Retinal dehydrogenase 1 | Homo sapiens (human) | 0.13 | |
| Aldehyde dehydrogenase, mitochondrial | Homo sapiens (human) | 3.4 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 4 | |
| Procathepsin L | Homo sapiens (human) | 9.35 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 4.904 | |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 1.3756 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 9.35 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 9.35 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 9.35 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.356 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.9171 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.356 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.218 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 2.158 | |
| D(4) dopamine receptor | Homo sapiens (human) | 3.15 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 6.013 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 1.51 | |
| Protein-lysine 6-oxidase | Homo sapiens (human) | 0.32 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 10 | |
| Caspase-1 | Homo sapiens (human) | 1.8 | |
| Mu-type opioid receptor | Homo sapiens (human) | 3.511 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.084 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 6.103 | |
| C-C chemokine receptor type 2 | Homo sapiens (human) | 2.468 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.356 | |
| C-C chemokine receptor type 4 | Homo sapiens (human) | 8.395 | |
| Gasdermin-D | Homo sapiens (human) | 0.4 | |
| Lysyl oxidase homolog 3 | Homo sapiens (human) | 0.093 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 9.35 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 4.637 | |
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | 3 | |
| Lysyl oxidase homolog 4 | Homo sapiens (human) | 0.059 | |
| Histone-lysine N-methyltransferase EHMT2 | Homo sapiens (human) | 0.6 | |
| Monoglyceride lipase | Homo sapiens (human) | 0.8095 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 9.35 | |
| Gasdermin-D | Mus musculus (house mouse) | 0.4 | |
| Histone-lysine N-methyltransferase EHMT1 | Homo sapiens (human) | 1.6 | |
| Lysyl oxidase homolog 2 | Homo sapiens (human) | 0.15 | |
| large T antigen | Betapolyomavirus macacae | 10.73 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for levofloxacin and disulfiram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for levofloxacin and disulfiram
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |